Is a $5 billions single product emerging? JPMorgan maintains “neutral” rating on Amgen (AMGN.US): A good drug does not equal a good buying point

智通财经2026/10/26 04:15

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data APP reports that JPMorgan's latest research note states that the first-line maintenance therapy data for Imdelltra, announced by Amgen (AMGN.US) at the ESMO conference last weekend, is "impressive" and may support the drug's advancement to earlier lines of treatment, potentially becoming a blockbuster worth 5 billion USD. However, the bank still maintains a "neutral" rating with a target price of 350 USD, which is lower than the current share price of approximately 439 USD.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Is a $5 billions single product emerging? JPMorgan maintains “neutral” rating on Amgen (AMGN.US): A good drug does not equal a good buying point

You may also like

Crypto prices